BethAOvermoyerMD

Oncology • Boston, MA

Breast Cancer, Cancer Genetics/Cancer Risk Assessment, Hematologic Oncology

Assistant Professor of Medicine, Dana Farber Cancer Institute

Join to view full profile

Dr. Overmoyer is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Overmoyer's full profile

Already have an account?

Office
44 Binney St
# 220B
Boston, MA 02115
Phone+1 617-632-3427

Fax+1 617-632-1930

Education & Training

University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 1989 - 1993
University of Pennsylvania Health SystemResidency, Internal Medicine, 1986 - 1989
Case Western Reserve University School of MedicineClass of 1986

Certifications & Licensure

MA State Medical License 2007 - 2026
OH State Medical License 1993 - 2010
CT State Medical License 2005 - 2009
PA State Medical License 1987 - 2006
American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

America's Top Doctors for Cancer Castle Connolly, 2016
Fellow (FACP) American College of Physicians, 2005
Super Doctor SuperDoctors.com

Clinical Trials

SU5416 and Doxorubicin in Treating Patients With Stage IIIB or Stage IV Inflammatory Breast Cancer Start of enrollment: 2000 Apr 01
Completed
Phase 1
Combination Chemotherapy in Treating Patients With Advanced Solid Tumors Start of enrollment: 2000 Feb 01
Completed
Phase 1
HER-2 Protein Vaccine in Treating Women With Breast Cancer Start of enrollment: 2003 Jul 01
Completed
Phase 1
Docetaxel, Doxorubicin, and Cyclophosphamide in Treating Women With Advanced Breast Cancer Start of enrollment: 2003 Sep 01
Withdrawn
Phase 1
Vaccination With Autologous Breast Cancer Cells Engineered to Secrete Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Metastatic Breast Cancer Patients Start of enrollment: 2006 Jan 01
Completed
Phase 1
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery Start of enrollment: 2009 May 15
Active, not recruiting
Phase 2
Autologous Vaccination With Lethally Irradiated, Autologous Breast Cancer Cells Engineered to Secrete GM-CSF in Women With Operable Breast Cancer Start of enrollment: 2006 Jan 01
Completed
Phase 1
Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa Start of enrollment: 2013 Aug 01
Active, not recruiting
Phase 2
Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca Start of enrollment: 2014 Feb 01
Completed
Phase 1, Phase 2
A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer Start of enrollment: 2016 Feb 26
Active, not recruiting
Phase 2
A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors Start of enrollment: 2018 Oct 25
Completed
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

Clinicogenomic characterization of inflammatory breast cancer.
Nolan Priedigkeit, Beth Harrison, Robert Shue, Melissa Hughes, Yvonne Li
Biorxiv. 2024-05-10
Abnormal vascular structure and function within brain metastases is linked to pembrolizumab resistance.
Albert E Kim, Kevin W Lou, Anita Giobbie-Hurder, Ken Chang, Mishka Gidwani
Neuro-Oncology. 2024-05-03
Clinical outcomes after 1 versus 2-3 lines of neoadjuvant therapy in stage III inflammatory breast cancer.
Faina Nakhlis, Samuel M Niman, Naoto T Ueno, Elizabeth Troll, Sean Ryan
Breast Cancer Research and Treatment. 2024-04-01

Journal Articles

Effect of Eribulin with or Without Pembrolizumab on Progression-Free Survival for Patients with Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer
Sara M Tolaney, Gerburg Wulf, Laura Spring, Beth Overmoyer, Ann H Partridge, Eric P Winer, Ian E Krop, JAMA Oncology
A Pharmacogenetic Prediction Model of Progression‐Free Survival in Breast Cancer Using Genome‐Wide Genotyping Data from CALGB 40502 (Alliance)
Hope S Rugo, Francisco Castillos, Beth Overmoyer, Mark J Ratain, Clinical Pharmacology & Therapeutics

Press Mentions

Breast Cancer: Common, Deadly and Preventable?October 25th, 2022
Enobosarm Shows Clinical Benefit in AR+, ER+ Metastatic Breast CancerJanuary 9th, 2021
Veru Expands Oncology Drug Pipeline; Exclusively Licenses Phase 3 Clinical Stage Targeted Therapy for Endocrine Resistant Metastatic Breast CancerDecember 9th, 2020
Join now to see all

Grant Support

SU5416 And Doxorubicin In Inflammatory Breast CancerNational Center For Research Resources2004
Pegylated Liposomal Doxorubicin + Vinorelbine + Gemcitabine For Solid TumorsNational Center For Research Resources2004
Fenretinide + Paclitaxel + Cisplatin For Advanced Solid TumorsNational Center For Research Resources2004
Bevacizumab And Docetaxel For Locally Advanced Breast CancerNational Center For Research Resources2004
Translational Research In Breast CancerNational Cancer Institute2000–2004
Core--Clinical Trials FacilityNational Cancer Institute2001–2002